{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:03:04Z","timestamp":1790971384111,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA236615-01"],"award-info":[{"award-number":["R01 CA236615-01"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA235667"],"award-info":[{"award-number":["R01 CA235667"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01 CA214195"],"award-info":[{"award-number":["U01 CA214195"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA170630"],"award-info":[{"award-number":["CA170630"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA180889"],"award-info":[{"award-number":["CA180889"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA200437"],"award-info":[{"award-number":["CA200437"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-023-00573-4","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T16:01:48Z","timestamp":1687190508000},"page":"1001-1015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation"],"prefix":"10.1038","volume":"4","author":[{"given":"Yuquan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7820-6829","authenticated-orcid":false,"given":"Meriem","family":"Taleb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Misawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srijita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Amador-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3318-0146","authenticated-orcid":false,"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-0977","authenticated-orcid":false,"given":"Navin K.","family":"Chintala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-2046","authenticated-orcid":false,"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"573_CR1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"573_CR2","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","volume":"18","author":"KM Cappell","year":"2021","unstructured":"Cappell, K. M. & Kochenderfer, J. N. A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains. Nat. Rev. Clin. Oncol. 18, 715\u2013727 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"573_CR3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser, R., Cherkassky, L., Chintala, N. & Adusumilli, P. S. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell 36, 471\u2013482 (2019).","journal-title":"Cancer Cell"},{"key":"573_CR4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.3389\/fimmu.2018.01104","volume":"9","author":"P Kosti","year":"2018","unstructured":"Kosti, P., Maher, J. & Arnold, J. N. Perspectives on chimeric antigen receptor T-cell immunotherapy for solid tumors. Front. Immunol. 9, 1104 (2018).","journal-title":"Front. Immunol."},{"key":"573_CR5","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1172\/JCI133215","volume":"130","author":"S Guedan","year":"2020","unstructured":"Guedan, S. et al. Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability. J. Clin. Invest. 130, 3087\u20133097 (2020).","journal-title":"J. Clin. Invest."},{"key":"573_CR6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/2326-6066.CIR-19-0908","volume":"8","author":"D Wijewarnasuriya","year":"2020","unstructured":"Wijewarnasuriya, D., Bebernitz, C., Lopez, A. V., Rafiq, S. & Brentjens, R. J. Excessive costimulation leads to dysfunction of adoptively transferred T cells. Cancer Immunol. Res. 8, 732\u2013742 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"573_CR7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1158\/2326-6066.CIR-19-0910","volume":"8","author":"DJ Drakes","year":"2020","unstructured":"Drakes, D. J. et al. Optimization of T-cell receptor-modified T cells for cancer therapy. Cancer Immunol. Res. 8, 743\u2013755 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"573_CR8","doi-asserted-by":"crossref","first-page":"708073","DOI":"10.3389\/fonc.2021.708073","volume":"11","author":"G Zuccolotto","year":"2021","unstructured":"Zuccolotto, G. et al. PSMA-specific CAR-engineered T cells for prostate cancer: CD28 outperforms combined CD28-4-1BB \u201csuper-stimulation\u201d. Front. Oncol. 11, 708073 (2021).","journal-title":"Front. Oncol."},{"key":"573_CR9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"573_CR10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","volume":"7","author":"T Shum","year":"2017","unstructured":"Shum, T. et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov. 7, 1238\u20131247 (2017).","journal-title":"Cancer Discov."},{"key":"573_CR11","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fimmu.2019.01691","volume":"10","author":"Y Wang","year":"2019","unstructured":"Wang, Y. et al. An IL-4\/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment. Front. Immunol. 10, 1691 (2019).","journal-title":"Front. Immunol."},{"key":"573_CR12","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-20-0777","volume":"26","author":"H Luo","year":"2020","unstructured":"Luo, H. et al. Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin. Cancer Res. 26, 5494\u20135505 (2020).","journal-title":"Clin. Cancer Res."},{"key":"573_CR13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41587-019-0398-2","volume":"38","author":"X Ma","year":"2020","unstructured":"Ma, X. et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat. Biotechnol. 38, 448\u2013459 (2020).","journal-title":"Nat. Biotechnol."},{"key":"573_CR14","first-page":"95","volume":"15","author":"ER Hawkins","year":"2021","unstructured":"Hawkins, E. R., D\u2019Souza, R. R. & Klampatsa, A. Armored CAR T-cells: the next chapter in T-cell cancer immunotherapy. Biologics 15, 95\u2013105 (2021).","journal-title":"Biologics"},{"key":"573_CR15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","volume":"24","author":"Y Kagoya","year":"2018","unstructured":"Kagoya, Y. et al. A novel chimeric antigen receptor containing a JAK\u2013STAT signaling domain mediates superior antitumor effects. Nat. Med. 24, 352\u2013359 (2018).","journal-title":"Nat. Med."},{"key":"573_CR16","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/MOH.0000000000000052","volume":"21","author":"S Rojas-Sutterlin","year":"2014","unstructured":"Rojas-Sutterlin, S., Lecuyer, E. & Hoang, T. Kit and Scl regulation of hematopoietic stem cells. Curr. Opin. Hematol. 21, 256\u2013264 (2014).","journal-title":"Curr. Opin. Hematol."},{"key":"573_CR17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.gene.2007.06.017","volume":"401","author":"S Ali","year":"2007","unstructured":"Ali, S. Role of c-Kit\/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 401, 38\u201345 (2007).","journal-title":"Gene"},{"key":"573_CR18","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","volume":"92","author":"J Lennartsson","year":"2012","unstructured":"Lennartsson, J. & R\u00f6nnstrand, L. Stem cell factor receptor\/c-Kit: from basic science to clinical implications. Physiol. Rev. 92, 1619\u20131649 (2012).","journal-title":"Physiol. Rev."},{"key":"573_CR19","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/nri937","volume":"2","author":"R Ceredig","year":"2002","unstructured":"Ceredig, R. & Rolink, T. A positive look at double-negative thymocytes. Nat. Rev. Immunol. 2, 888\u2013897 (2002).","journal-title":"Nat. Rev. Immunol."},{"key":"573_CR20","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1182\/blood.V88.10.3887.bloodjournal88103887","volume":"88","author":"EM Bluman","year":"1996","unstructured":"Bluman, E. M. et al. The c-Kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood 88, 3887\u20133893 (1996).","journal-title":"Blood"},{"key":"573_CR21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fimmu.2019.00468","volume":"10","author":"G Frumento","year":"2019","unstructured":"Frumento, G. et al. CD117 (c-Kit) is expressed during CD8+ T cell priming and stratifies sensitivity to apoptosis according to strength of TCR engagement. Front. Immunol. 10, 468 (2019).","journal-title":"Front. Immunol."},{"key":"573_CR22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.iac.2018.04.005","volume":"38","author":"L Falchi","year":"2018","unstructured":"Falchi, L. & Verstovsek, S. Kit mutations: new insights and diagnostic value. Immunol. Allergy Clin. North Am. 38, 411\u2013428 (2018).","journal-title":"Immunol. Allergy Clin. North Am."},{"key":"573_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.mrfmmm.2018.02.001","volume":"808","author":"PK Raghav","year":"2018","unstructured":"Raghav, P. K., Singh, A. K. & Gangenahalli, G. A change in structural integrity of c-Kit mutant D816V causes constitutive signaling. Mutat. Res. 808, 28\u201338 (2018).","journal-title":"Mutat. Res."},{"key":"573_CR24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota, S. et al. Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors. Science 279, 577\u2013580 (1998).","journal-title":"Science"},{"key":"573_CR25","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","volume":"12","author":"BJ Longley","year":"1996","unstructured":"Longley, B. J. et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12, 312\u2013314 (1996).","journal-title":"Nat. Genet."},{"key":"573_CR26","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V95.2.726","volume":"95","author":"A Beghini","year":"2000","unstructured":"Beghini, A. et al. c-Kit mutations in core binding factor leukemias. Blood 95, 726\u2013727 (2000).","journal-title":"Blood"},{"key":"573_CR27","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","volume":"29","author":"M Jawhar","year":"2015","unstructured":"Jawhar, M. et al. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia 29, 1115\u20131122 (2015).","journal-title":"Leukemia"},{"key":"573_CR28","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2147\/DDDT.S89114","volume":"10","author":"M Abbaspour Babaei","year":"2016","unstructured":"Abbaspour Babaei, M., Kamalidehghan, B., Saleem, M., Huri, H. Z. & Ahmadipour, F. Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells. Drug Des. Devel. Ther. 10, 2443\u20132459 (2016).","journal-title":"Drug Des. Devel. Ther."},{"key":"573_CR29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.exphem.2017.05.003","volume":"52","author":"I Omori","year":"2017","unstructured":"Omori, I. et al. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia. Exp. Hematol. 52, 56\u201364 (2017).","journal-title":"Exp. Hematol."},{"key":"573_CR30","doi-asserted-by":"crossref","unstructured":"Orfao, A., Garcia-Montero, A. C., Sanchez, L. & Escribano, L., REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br. J. Haematol. 138, 12\u201330 (2007).","DOI":"10.1111\/j.1365-2141.2007.06619.x"},{"key":"573_CR31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/MCB.01153-06","volume":"27","author":"Z Xiang","year":"2007","unstructured":"Xiang, Z., Kreisel, F., Cain, J., Colson, A. & Tomasson, M. H. Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol. Cell. Biol. 27, 267\u2013282 (2007).","journal-title":"Mol. Cell. Biol."},{"key":"573_CR32","doi-asserted-by":"crossref","first-page":"5956","DOI":"10.1074\/jbc.M110.182642","volume":"286","author":"A Chaix","year":"2011","unstructured":"Chaix, A. et al. Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J. Biol. Chem. 286, 5956\u20135966 (2011).","journal-title":"J. Biol. Chem."},{"key":"573_CR33","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","volume":"112","author":"N Harir","year":"2008","unstructured":"Harir, N. et al. Oncogenic Kit controls neoplastic mast cell growth through a STAT5\/PI3-kinase signaling cascade. Blood 112, 2463\u20132473 (2008).","journal-title":"Blood"},{"key":"573_CR34","doi-asserted-by":"crossref","DOI":"10.1038\/s41389-019-0148-9","volume":"8","author":"C Larrue","year":"2019","unstructured":"Larrue, C. et al. Oncogenic KIT mutations induce STAT3-dependent autophagy to support cell proliferation in acute myeloid leukemia. Oncogenesis 8, 39 (2019).","journal-title":"Oncogenesis"},{"key":"573_CR35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.molcel.2018.08.040","volume":"72","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. The proto-oncogene c-Kit inhibits tumor growth by behaving as a dependence receptor. Mol. Cell 72, 413\u2013425 (2018).","journal-title":"Mol. Cell"},{"key":"573_CR36","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","volume":"6","author":"PS Adusumilli","year":"2014","unstructured":"Adusumilli, P. S. et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6, 261ra151 (2014).","journal-title":"Sci. Transl. Med."},{"key":"573_CR37","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","volume":"126","author":"L Cherkassky","year":"2016","unstructured":"Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130\u20133144 (2016).","journal-title":"J. Clin. Invest."},{"key":"573_CR38","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","volume":"11","author":"PS Adusumilli","year":"2021","unstructured":"Adusumilli, P. S. et al. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. Cancer Discov. 11, 2748\u20132763 (2021).","journal-title":"Cancer Discov."},{"key":"573_CR39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2022.01.003","volume":"165","author":"M Ghosn","year":"2022","unstructured":"Ghosn, M. et al. Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I\/II clinical trial. Lung Cancer 165, 1\u20139 (2022).","journal-title":"Lung Cancer"},{"key":"573_CR40","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2022.04.006","volume":"40","author":"L Cherkassky","year":"2022","unstructured":"Cherkassky, L., Hou, Z., Amador-Molina, A. & Adusumilli, P. S. Regional CAR T cell therapy: an ignition key for systemic immunity in solid tumors. Cancer Cell 40, 569\u2013574 (2022).","journal-title":"Cancer Cell"},{"key":"573_CR41","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1073\/pnas.1913940117","volume":"117","author":"BP Nicolet","year":"2020","unstructured":"Nicolet, B. P. et al. CD29 identifies IFN-\u03b3-producing human CD8. Proc. Natl Acad. Sci. USA 117, 6686\u20136696 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"573_CR42","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.67","volume":"8","author":"P Bhat","year":"2017","unstructured":"Bhat, P., Leggatt, G., Waterhouse, N. & Frazer, I. H. Interferon-\u03b3 derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity. Cell Death Dis. 8, e2836 (2017).","journal-title":"Cell Death Dis"},{"key":"573_CR43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1126\/science.3131876","volume":"240","author":"KA Smith","year":"1988","unstructured":"Smith, K. A. Interleukin-2: inception, impact, and implications. Science 240, 1169\u20131176 (1988).","journal-title":"Science"},{"key":"573_CR44","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1357-2725(99)00078-3","volume":"31","author":"D Linnekin","year":"1999","unstructured":"Linnekin, D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int. J. Biochem. Cell Biol. 31, 1053\u20131074 (1999).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"573_CR45","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"573_CR46","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","volume":"17","author":"L Gattinoni","year":"2011","unstructured":"Gattinoni, L. et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17, 1290\u20131297 (2011).","journal-title":"Nat. Med."},{"key":"573_CR47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/17826","volume":"397","author":"L Ulloa","year":"1999","unstructured":"Ulloa, L., Doody, J. & Massagu\u00e9, J. Inhibition of transforming growth factor-\u03b2\/SMAD signalling by the interferon-\u03b3\/STAT pathway. Nature 397, 710\u2013713 (1999).","journal-title":"Nature"},{"key":"573_CR48","doi-asserted-by":"crossref","first-page":"7838","DOI":"10.1038\/sj.onc.1207046","volume":"22","author":"H Kuga","year":"2003","unstructured":"Kuga, H. et al. Interferon-\u03b3 suppresses transforming growth factor-\u03b2-induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model. Oncogene 22, 7838\u20137847 (2003).","journal-title":"Oncogene"},{"key":"573_CR49","volume":"10","author":"J Koh","year":"2020","unstructured":"Koh, J. et al. Regulatory (FoxP3+) T cells and TGF-\u03b2 predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer. Sci. Rep. 10, 18994 (2020).","journal-title":"Sci. Rep."},{"key":"573_CR50","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/1097-0142(20010301)91:5<964::AID-CNCR1086>3.0.CO;2-O","volume":"91","author":"Y Hasegawa","year":"2001","unstructured":"Hasegawa, Y. et al. Transforming growth factor-\u03b21 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91, 964\u2013971 (2001).","journal-title":"Cancer"},{"key":"573_CR51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/5584_2015_115","volume":"852","author":"K Jakubowska","year":"2015","unstructured":"Jakubowska, K., Naumnik, W., Niklinska, W. & Chyczewska, E. Clinical significance of HMGB-1 and TGF-\u03b2 level in serum and BALF of advanced non-small cell lung cancer. Adv. Exp. Med. Biol. 852, 49\u201358 (2015).","journal-title":"Adv. Exp. Med. Biol."},{"key":"573_CR52","doi-asserted-by":"crossref","first-page":"155622","DOI":"10.1016\/j.cyto.2021.155622","volume":"146","author":"L Urso","year":"2021","unstructured":"Urso, L. et al. Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification. Cytokine 146, 155622 (2021).","journal-title":"Cytokine"},{"key":"573_CR53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","volume":"139","author":"P Stockhammer","year":"2020","unstructured":"Stockhammer, P. et al. Detection of TGF-\u03b2 in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma. Lung Cancer 139, 124\u2013132 (2020).","journal-title":"Lung Cancer"},{"key":"573_CR54","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"573_CR55","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1158\/1535-7163.MCT-08-0945","volume":"8","author":"Y Feng","year":"2009","unstructured":"Feng, Y. et al. A novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity. Mol. Cancer Ther. 8, 1113\u20131118 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"573_CR56","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","volume":"567","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. NR4A transcription factors limit CAR T cell function in solid tumours. Nature 567, 530\u2013534 (2019).","journal-title":"Nature"},{"key":"573_CR57","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"573_CR58","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.celrep.2017.05.013","volume":"19","author":"SK Tripathi","year":"2017","unstructured":"Tripathi, S. K. et al. Genome-wide analysis of STAT3-mediated transcription during early human TH17 cell differentiation. Cell Rep. 19, 1888\u20131901 (2017).","journal-title":"Cell Rep."},{"key":"573_CR59","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41590-021-00964-8","volume":"22","author":"H Seo","year":"2021","unstructured":"Seo, H. et al. BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat. Immunol. 22, 983\u2013995 (2021).","journal-title":"Nat. Immunol."},{"key":"573_CR60","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","volume":"26","author":"G Fuc\u00e0","year":"2020","unstructured":"Fuc\u00e0, G., Reppel, L., Landoni, E., Savoldo, B. & Dotti, G. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin. Cancer Res. 26, 2444\u20132451 (2020).","journal-title":"Clin. Cancer Res."},{"key":"573_CR61","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/biomedicines6010031","volume":"6","author":"BM Foster","year":"2018","unstructured":"Foster, B. M., Zaidi, D., Young, T. R., Mobley, M. E. & Kerr, B. A. CD117\/c-Kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines 6, 31 (2018).","journal-title":"Biomedicines"},{"key":"573_CR62","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41423-019-0245-x","volume":"17","author":"MP Pistillo","year":"2020","unstructured":"Pistillo, M. P. et al. IFN-\u03b3 upregulates membranous and soluble PD-L1 in mesothelioma cells: potential implications for the clinical response to PD-1\/PD-L1 blockade. Cell. Mol. Immunol. 17, 410\u2013411 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"573_CR63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","volume":"51","author":"N Chen","year":"2018","unstructured":"Chen, N., Li, X., Chintala, N. K., Tano, Z. E. & Adusumilli, P. S. Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr. Opin. Immunol. 51, 103\u2013110 (2018).","journal-title":"Curr. Opin. Immunol."},{"key":"573_CR64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6, 133\u2013146 (2016).","journal-title":"Cancer Discov."},{"key":"573_CR65","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1182\/blood.V90.11.4539","volume":"90","author":"P Ferrao","year":"1997","unstructured":"Ferrao, P., Gonda, T. J. & Ashman, L. K. Expression of constitutively activated human c-Kit in Myb transformed early myeloid cells leads to factor independence, histiocytic differentiation, and tumorigenicity. Blood 90, 4539\u20134552 (1997).","journal-title":"Blood"},{"key":"573_CR66","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.4049\/jimmunol.163.3.1133","volume":"163","author":"H Sepulveda","year":"1999","unstructured":"Sepulveda, H., Cerwenka, A., Morgan, T. & Dutton, R. W. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J. Immunol. 163, 1133\u20131142 (1999).","journal-title":"J. Immunol."},{"key":"573_CR67","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1084\/jem.178.3.1079","volume":"178","author":"ME Matos","year":"1993","unstructured":"Matos, M. E. et al. Expression of a functional c-Kit receptor on a subset of natural killer cells. J. Exp. Med. 178, 1079\u20131084 (1993).","journal-title":"J. Exp. Med."},{"key":"573_CR68","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli, A. et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 126, 458\u2013465 (2009).","journal-title":"Immunology"},{"key":"573_CR69","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","volume":"1","author":"MC Gong","year":"1999","unstructured":"Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123\u2013127 (1999).","journal-title":"Neoplasia"},{"key":"573_CR70","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cyto.a.10072","volume":"55","author":"PO Krutzik","year":"2003","unstructured":"Krutzik, P. O. & Nolan, G. P. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55, 61\u201370 (2003).","journal-title":"Cytometry A"},{"key":"573_CR71","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"573_CR72","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/nmeth.2722","volume":"10","author":"PG Engstr\u00f6m","year":"2013","unstructured":"Engstr\u00f6m, P. G. et al. Systematic evaluation of spliced alignment programs for RNA-seq data. Nat. Methods 10, 1185\u20131191 (2013).","journal-title":"Nat. Methods"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00573-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00573-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T23:04:32Z","timestamp":1690326272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-023-00573-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":72,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["573"],"URL":"https:\/\/doi.org\/10.1038\/s43018-023-00573-4","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.X. and P.S.A. have a pending patent application on the KITv mutation as a co-stimulatory domain to use in T cells. P.S.A. declares research funding from ATARA Biotherapeutics and Novocure; is a scientific advisory board member and consultant for Adjuvant Genomics, ATARA Biotherapeutics, Abound Bio, Bio4t2, Carisma Therapeutics, Imugene, ImmPACT Bio, Johnson & Johnson, Link Immunotherapeutics, Orion Pharma, Outpace Bio, Pluri-biotech, Putnam Associates and Verismo Therapeutics; has patents, royalties and intellectual property on MSLN-targeted CAR and other T cell therapies licensed to ATARA Biotherapeutics; has issued a patent method for the detection of cancer cells using virus; and has pending patent applications on PD-1 dominant-negative receptors, a wireless pulse-oximetry device and an ex vivo malignant pleural effusion culture system. All other authors declare no competing interests. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to MSLN-targeted CARs and T cell therapies to ATARA Biotherapeutics and has associated financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}